The prognosis of non-small cell lung cancer patients according to endobronchial metastatic lesion

The prognosis of non-small cell lung cancer patients according to endobronchial metastatic lesion

To evaluate the prognosis of non-small cell lung cancer (NSCLC) patients according to endobronchial metastatic lesion (EML), especially those not identified on positron emission tomography or computed tomography. We evaluated progression-free survival (PFS) and overall survival (OS) according to the presence of EML in patients with NSCLC who were diagnosed at a tertiary hospital between January 2010 and December 2019. A total of 364 patients wer…

Cancer associated fibroblast drives spheroid formation and pleural dissemination in non-small cell lung cancer

Pleural dissemination in non-small cell lung cancer (NSCLC) refers to cancer cells directly spreading from the primary tumor to the extrapulmonary thoracic cavity, where they colonize the pleura. This study investigated the impact of cancer-associated fibroblasts (CAFs) on the development of pleu...

Recent Clinical Trial Highlights for NSCLC Treatment

A panelist discusses how recent clinical trials for EGFR-positive non–small cell lung cancer (NSCLC) have expanded treatment options beyond single oral agents, with studies like FLAURA2, MARIPOSA, and PAPILLON demonstrating significant improvements in progression-free survival for combination therapies such as osimertinib plus chemotherapy and amivantamab plus lazertinib, though these combinations often come with higher rates of toxicity, discon…

Optune Lua Granted CE Mark Approval in EU for Metastatic NSCLC

A CE Mark has been granted to Optune Lua concurrent with immune checkpoint inhibitors or docetaxel for patients with metastatic non–small cell lung cancer.

Optune Lua Receives CE Mark in Europe for Metastatic NSCLC

Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.

TTFields Therapy Earns EU Approval in Metastatic Non–Small Cell Lung Cancer

Data from the phase 3 LUNAR trial support the Conformité Européenne Mark for tumor treating fields in metastatic non–small cell lung cancer.